KRAS and pancreatic neoplasm: The identification of lectins that bind predominantly to KRAS mutant organoids compared to KRAS wild-type organoids may contribute to the development of markers that recognize KRAS mutant pancreatic cancer cells and cancer proteins for CTC and hematological diagnosis.